

Editor

Leo van de Putte (Nijmegen)

Associate editors

Thomas Bardin (Paris)
Johannes Bijlsma (Utrecht)
Gerd Burmester (Berlin)
Bevrah Hahn (Los Angeles)
Frank Wollheim (Lund)
Anthony Woolf (Truro)

Methodological adviser

Jaap Fransen (Nijmegen)

Editorial board

Martin Aringer (Vienna)
Paul Bacon (Birmingham)
Francis Berenbaum (Paris)
Maarten Boers (Amsterdam)
Dimitrios Boumpas (Heraklion)
Barry Bresnihan (Dublin)
Hillary Capell (Glasgow)
Maurizio Cutolo (Genova)
Gary Firestein (La Jolla San Diego)
Philippe Goupille (Tours)
Ellen Gravallese (Boston)
Wolfgang Gross (Bad Bramstedt)
Francis Guillemain (Nancy)
Gabriel Herrero-Beaumont (Madrid)
Frederic Houssiau (Brussels)
Tom Huizinga (Leiden)
Christian Jorgensen (Montpellier)
George Kollias (Athens)
Tore Kvien (Oslo)
Marjatta Leirisalo-Repo (Lund)
Frank Luijten (Leuven)
Hanns-Martin Lorenz (Heidelberg)

W Maslinski (Poland)
Marco Matucci Cerinic (Florence)
Kusuki Nishioka (Kanagawa)
Seza Özen (Ankara)
Thomas Pap (Magdeburg)
Eliseo Pascual Gómez (Alicante)
Leonardo Punzi (Padova)
Lars Rönnblom (Uppsala)
Blaž Rozman (Ljubljana)
Georg Schett (Vienna)
José Da Silva (Coimbra)
Hendrik Schulze-Koops (Erlangen)
Alex So (Lausanne)
Tuulikki Sokka (Nashville)
Deborah Symmons (Manchester)
Paul-Peter Tak (Amsterdam)
Alan Tyndall (Basel)
Athanasios Tzioufas (Athens)
Jiří Vencovsky (Praha)
Michael Ward (Bethesda)
Michael Weisman (Los Angeles)
Hasan Yazici (Istanbul)
Editor, *BMJ*

Advisory committee

Wim vd Berg (Nijmegen)
Stefano Bombardieri (Pisa)
Ferdinand Breedveld (Leiden)
Leslie Crofford (Michigan)
Jean-Michel Dayer (Geneva)
Mike Doherty (Nottingham)
Maxime Dougados (Paris)
John Edmonds (Sydney)
Paul Emery (Leeds)
Daniel Furst (Seattle)
Steffen Gay (Zurich)
Joachim Kalden (Erlangen)
Edward Keystone (Toronto)
Lars Klareskog (Stockholm)
Peter Lipsky (Dallas)
Stefan Lohmander (Lund)
Ravinder Maini (London)
Emilio Martin Mola (Madrid)
Haralampos Moutsopoulos (Athens)
James O'Dell (Omaha)
Karel Pavelka (Prague)
Josef Rovinsky (Piestany)
Yehuda Shoenfeld (Tel-Hashomer)
Josef Smolen (Vienna)
Walther van Venrooy (Nijmegen)
Eric Veys (Gent)
Allan Wiik (Denmark)

Instructions to authors

All papers must be submitted via BenchPress at <http://submit-ard.bmjournals.com/>

Subscription information


See p iv

Copyright

© 2006 BMJ Publishing Group and European League Against Rheumatism. All rights reserved; no part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise without the prior permission of *Annals of the Rheumatic Diseases*

Authors are required to grant *Annals of the Rheumatic Diseases* an exclusive licence to publish; further details available online at www.annrheumdis.com/misc/afora.shtml

• *Annals of the Rheumatic Diseases* is published by BMJ Publishing Group, typeset by The Charlesworth Group, and printed in the UK on acid-free paper by Unwin Brothers, Woking
• Periodicals postage paid, Rahway, NJ. Postmaster: send address changes to: *Annals of the Rheumatic Diseases*, c/o Mercury Airfreight International Ltd, 365 Blair Road, Avenel, NJ 07001, USA



Achilles tendon xanthomas (upper) and a stained microscopic section (lower). See p. 312



Editorial

281 Persistent infection of *Chlamydia* in reactive arthritis M Rihl, L Köhler, A Klos, H Zeidler

Review

285 Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data J A P Da Silva, J W G Jacobs, J R Kirwan, M Boers, K G Saag, L B S Inês, E J P de Koning, F Buttgereit, M Cutolo, H Capell, R Rau, J W J Bijlsma

Extended reports

294 Chemokine and chemokine receptor expression in paired peripheral blood mononuclear cells and synovial tissue of patients with rheumatoid arthritis, osteoarthritis, and reactive arthritis J J Haringman, T J M Smeets, P Reinders-Blankert, P P Tak

301 Anti-TNF antibody treatment improves glucocorticoid induced insulin-like growth factor 1 (IGF1) resistance without influencing myoglobin and IGF1 binding proteins 1 and 3 P Sarzi-Puttini, F Atzeni, J Schölmerich, M Cutolo, R H Straub

306 Thermal signature analysis as a novel method for evaluating inflammatory arthritis activity M Brenner, C Braun, M Oster, P S Gulko

312 Familial hypercholesterolaemia commonly presents with Achilles tenosynovitis D Beeharry, B Coupe, E W Benbow, J Morgan, S Kwok, V Charlton-Menys, M France, P N Durrington

316 First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis J Braun, J Davis, M Dougados, J Sieper, S van der Linden, D van der Heijde, for the ASAS Working Group

321 Synovial *Chlamydia trachomatis* up regulates expression of a panel of genes similar to that transcribed by *Mycobacterium tuberculosis* during persistent infection H C Gérard, J A Whittum-Hudson, H R Schumacher, A P Hudson

328 Patient reported outcomes in a trial of combination therapy with etanercept and methotrexate for rheumatoid arthritis: the TEMPO trial D van der Heijde, L Klareskog, A Singh, J Tornero, J Melo-Gomes, C Codreanu, R Pedersen, B Freundlich, S Fatenejad

335 Orthopaedic surgery of the lower limbs in 49 802 rheumatoid arthritis patients: results from the Swedish National Inpatient Registry during 1987 to 2001 R J Weiss, A Stark, M C Wick, A Ehlin, K Palmblad, P Wretenberg

342 The shared epitope is a marker of severity associated with selection for, but not with response to, infliximab in a large rheumatoid arthritis population H Marotte, B Pallot-Prades, L Grange, J Tebib, P Gaudin, C Alexandre, J L Blond, M A Cazalis, B Mouglin, P Miossec



This logo indicates an article that was published online first ahead of print

- 348 Excess recurrent cardiac events in rheumatoid arthritis patients with acute coronary syndrome *K M J Douglas, A V Pace, G J Treharne, A Saratzis, P Nightingale, N Erb, M J Banks, G D Kitas*
- 354 Molecular markers of cartilage breakdown and synovitis at baseline as predictors of structural progression of hip osteoarthritis. The ECHODIAH Cohort *B Mazières, P Garnero, A Guéguen, M Abbal, L Berdah, M Lequesne, M Nguyen, J-P Salles, E Vignon, M Dougados*
- 360 Urinary CTX-II levels are associated with radiographic subtypes of osteoarthritis in hip, knee, hand, and facet joints in subject with familial osteoarthritis at multiple sites: the GARP study *I Meulenbelt, M Kloppenburg, H M Kroon, J J Houwing-Duistermaat, P Garnero, M-P Hellio Le Graverand, J DeGroot, P E Slagboom*
- 366 Smoking is a risk factor for anti-CCP antibodies only in rheumatoid arthritis patients who carry HLA-DRB1 shared epitope alleles *S P Linn-Rasker, A H M van der Helm-van Mil, F A van Gaalen, M Kloppenburg, R R P de Vries, S le Cessie, F C Breedveld, R E M Toes, T W J Huizinga*
- 372 Aberrant TNF secretion by whole blood in healthy subjects with a history of reactive arthritis: time course in adherent and non-adherent cultures *K Anttonen, A Orpana, M Leirisalo-Repo, H Repo*
- 379 Long term safety of etanercept in elderly subjects with rheumatic diseases *R Fleischmann, S W Baumgartner, M H Weisman, T Liu, B White, P Peloso*
- 385 Antimalarial myopathy: an underdiagnosed complication? Prospective longitudinal study of 119 patients *E Casado, J Gratacós, C Tolosa, J M Martínez, I Ojanguren, A Ariza, J Real, A Sanjuan, M Larrosa*

Concise reports

- 391 Does physical trauma lead to an increase in the risk of new onset widespread pain? *G Wynne-Jones, G J Macfarlane, A J Silman, G T Jones*
- 394 Anti-cyclic citrullinated peptide antibodies in hepatitis C virus associated rheumatological manifestations and Sjögren's syndrome *D Sène, P Ghillani-Dalbin, N Limal, V Thibault, T van Boekel, J-C Piette, P Cacoub*
- 398 Antibodies against cyclic citrullinated peptide (CCP) in psoriatic patients with or without joint inflammation *G M Alenius, E Berglin, S Rantapää Dahlqvist*

- 401 Growth and infectious exposure during infancy and the risk of rheumatoid factor in adult life *C J Edwards, R Goswami, P Goswami, H Syddall, E M Dennison, N K Arden, C Cooper*
- 405 New onset or exacerbation of psoriatic skin lesions in patients with definite rheumatoid arthritis receiving tumour necrosis factor α antagonists *S Kary, M Worm, H Audring, D Huscher, M Renelt, H Sörensen, E Ständer, U Maaß, H Lee, W Sterry, G-R Burmester*

Letters

- 408 Antiphospholipid antibody syndrome associated with primary angiitis of the central nervous system: report of two biopsy proven cases *M Quintero, N Mirza, H Chang, A Perl*
- 410 ANCA associated glomerulonephritis in a patient with mixed connective tissue disease *G Hernández-Molina, E Reyes, J C Crispín*
- 411 Three dimensional power Doppler ultrasonography confirms early reduction of synovial perfusion after intra-articular steroid injection *J Strunk, K Strube, U Müller-Ladner, U Lange*
- 413 Alveolar and serum antiphospholipid antibodies in acute respiratory distress syndrome associated with catastrophic antiphospholipid syndrome *F J Wiedermann*
- 414 Dupuytren's contracture is associated with sprouting of substance P positive nerve fibres and infiltration by mast cells *T E O Schubert, C Weidler, N Borisch, C Schubert, F Hofstädter, R H Straub*
- 415 Arterial stiffness in Behçet's disease: increased regional pulse wave velocity values *H K Chang, S K Kim, S S Lee, M Y Rhee*
- 417 Safety and efficacy of leflunomide in the treatment of lupus nephritis refractory or intolerant to traditional immunosuppressive therapy: an open label trial *L-S Tam, E K Li, C-K Wong, C W K Lam, W-C Li, C-C Szeto*
- 418 No evidence of parvovirus B19 in tissue samples from patients with polyarteritis nodosa and microscopic polyangiitis as assessed by the polymerase chain reaction *Z Sachetto, S C B Costa, P D Andrade, R A Conde, E M I Amstalden, A M Samara, S R M Fernandes*
- 420 Correction
- 420 Forthcoming events